Recruiting

High-Flow Oxygen Therapy

Sponsor:

Laval University

Code:

NCT07168213

Conditions

Oxygen Delivery

Acute Respiratory Failure

High Flow Oxygen Therapy

Hypoxemic Acute Respiratory Failure

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Manual FiO2 titration with Philips oximeter (SpO2 target 90%)

Manual FiO2 titration with Nonin oximeter (SpO2 target 90%)

Manual FiO2 titration with Philips oximeter (SpO2 target 94%)

Manual FiO2 titration with Nonin oximeter (SpO2 target 94%)

Study Details

Brief summary:

Several factors can influence oxygenation monitoring and respiratory support through oxygen therapy: the type of oximeter used, skin pigmentation, and the oxygenation target. It is essential to have an accurate measurement of SpO2 in order to optimize the flow of oxygen or FiO2 administered to patients. The question arises as to the impact of these confounding factors on the FiO2 set during high-flow nasal oxygen therapy. The aim of the study is to evaluate the impact of the oxygenation target and the oximeter used on FiO2 in patients receiving high-flow nasal oxygen therapy.

Conditions

Oxygen Delivery

Acute Respiratory Failure

High Flow Oxygen Therapy

Hypoxemic Acute Respiratory Failure

Study ID

NCT07168213

Start date

Oct 21, 2025

Status verified date

Feb, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • ≥ 18 years of age
  • Admiitted in intensive care unit
  • Presence of an arterial catheter
  • Ongoing on high flow nasal oxygen therapy with SpO2 between 88 and 100% with a FiO2 between 40 and 80% with the usual oximeter .

Exclusion Criteria:

  • No SpO2 signal with oximeter in use
  • False nails or nail polish
  • Methemoglobinemia >0.015 on last available arterial gas
  • Patient in isolation (multi-resistant bacteria, C-Difficile, SARS-CoV-2 ...)
  • Expected to use another respiratory support within two hour of inclusion (NIV or mechanical ventilation)

Study Design

Enrollment

30 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Nonin oximeter with a 90% SpO2 target

During this periods , oxygen through high flow nasal therapy a will be administered in an manual titration to reach 90% of SpO2.

experimental: Philips oximeter with a 90% SpO2 target

During this periods , oxygen through high flow nasal therapy a will be administered in an manual titration to reach 90% of SpO2.

experimental: Nonin oximeter with a 94% SpO2 target

During this periods , oxygen through high flow nasal therapy a will be administered in an manual titration to reach 94% of SpO2.

experimental: Philips oximeter with a 94% SpO2 target

During this periods , oxygen through high flow nasal therapy a will be administered in an manual titration to reach 94% of SpO2.

Interventions

Manual FiO2 titration with Philips oximeter (SpO2 target 90%)

FiO2 titration to reach the SpO2 target (set at 90%) with Philips oximeter

Manual FiO2 titration with Nonin oximeter (SpO2 target 90%)

FiO2 titration to reach the SpO2 target (set at 90%) with Nonin oximeter

Manual FiO2 titration with Philips oximeter (SpO2 target 94%)

FiO2 titration to reach the SpO2 target (set at 94%) with Philips oximeter

Manual FiO2 titration with Nonin oximeter (SpO2 target 94%)

FiO2 titration to reach the SpO2 target (set at 94%) with Nonin oximeter

Primary outcome measure

  • FiO2 [ Time Frame: Mean FiO2 in the two last minute of each study period between minute 8 and 10 ]

Central Contacts and Locations

Central contacts

Francois Lellouche Principal Investigator

418-656-8711francois.lellouche@criucpq.ulaval.ca

Locations

Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval

Recruiting

Québec, Quebec, Canada, G1V4G5

Contacts

Francois Lellouche

418-656-8711francois.lellouche@criucpq.ulaval.ca

More Information

Sponsor

Laval University

Last update posted

Mar 9, 2026

Last verified

Feb, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Laval University on 2026-03-09.